UNSPSC 51101663: Imidocarb

This classification denotes an antiprotozoal agent with the molecular formula C19H20N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8USS3K0VDH, chemically known as 3,3-di-2-imidazolin-2-ylcarbanilide dihydrochloride but generally known as imidocarb, which bears US NIH Compound Identifier 21389. European Medicines Agency schedules Imidocarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08146MIG.

UNSPSC 51101663 Imidocarb is a Commodity code, but the recent state and local opportunities posted under this designation do not reflect purchases of imidocarb (an antiprotozoal veterinary pharmaceutical) or related products. Instead, the code shows activity in naloxone procurement, emergency medical supplies, direct-to-manufacturer pharmacy programs, and generic pharmaceuticals—a mismatch between the code's stated scope and what state and local governments are actually buying. The issuing bodies are diverse: Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance. Work ranges from annual purchases of naloxone and drug deactivation systems for community health to competitive bidding for medical and first aid supplies for fire rescue operations, exploratory requests for information on direct pharmacy contracting models, and multi-state cooperative procurement of generic pharmaceuticals and OTC products.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The City of Tampa released ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division—an estimated $700,000 contract with a March 13, 2026 due date, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs serving self-insured health plans and state agencies, representing early-stage procurement strategy development rather than a formal competitive solicitation.